Clinical Trials in Oncology

Innovative approaches to overcoming the practical challenges of clinical trials in oncology; cutting edge technologies and strategies to optimise the development of targeted, next-gen cancer therapies

29-30 November and 1 December 2010 – Munich, Germany

Oncology is the fastest growing area within the pharmaceutical industry. The market is expected to surpass US$78 billion by 2012 and the market for cancer biotherapy treatment is predicted to reach US$60 billion in the next 10 years. With vast opportunities to be had in this rapidly evolving field, the pressure is on for pharma and biotech companies alike to discover innovative and effective therapies and launch them as quickly and seamlessly as possible.

Through case study driven presentations from leading pharmaceutical and biotech companies, panel discussions, and a series of interactive roundtable discussions, this event will provide strategic, scientific, and operational solutions to face the current and upcoming challenges in the field.

• Take away applicable, implementable strategies relevant to your ongoing and future trials and development plans from successful case studies
• Exploit new opportunities in targeted therapies whilst mitigating risks

• Learn directly from the leaders and implementers of cutting edge biomarker and adaptive projects

• Explore what works and what doesn’t in oncology drug development in Europe and further afield, through the lessons learned by operational experts, project leaders, and regulatory authorities in clinical trials in oncology

Learn how to:

• Expedite and strengthen Phases I-III through innovative and effective proven methods of improving suitability of trial setup
• Optimise candidate and investigator engagement and patient recruitment through use of innovative and effective marketing of your trial within varying European guidelines
• Exploit opportunities, possibilities and rewards of biomarker-led drug development through establishing how to tackle the hurdles and minimise procedural obstacles in adaptive trials and personalised medicine
• Achieve optimal trial development through full understanding of regulation, exploitation of regulatory advisory services and tips on time-effective application and submission
• Select the most suitable primary endpoint to ensure positive implications for cost control, funding, licensing and reimbursement

Key speakers include:

• Professor John Crown, MD, MBA,Consultant Medical Oncologist, St Vincent’s University Hospital, Dublin, Ireland, Thomas Baldwin Chair in Translational Cancer Research, Dublin City University, Health Research Board Clinician Scientist, Chair of the Breast Disease Specific Sub-Group, All Ireland Co-Operative Oncology Research Group (ICORG, Director of Molecular Therapeutics for Cancer Ireland, Strategic Research Cluster)
• Dr Carmen Marqués, Head Pharma Development Operation, Medical Director, Roche
• Dr Grégoire Prevost, Director Oncology Research, IPSEN
• Silvia Chioato, Pharm. D., Global Portfolio Regulatory Lead, Worldwide Regulatory Strategy, Oncology , Pfizer
• Mohammed Raza (Raz) Dewji, Sarcoma Indication Team Leader, Oncology R&D Unit , GlaxoSmithKline
• Helen Chung, Associate Director, NICE
• Karin Hummel, Regional Clinical Operations Manager, DACH Region, Bristol Myers-Squibb
• Professor Karol Sikora, Medical Director , CancerPartnersUK
• Przemyslaw Brzeski M.D, Therapeutic Group Leader , Oncology, Pharma Development Operations, Central and Eastern Europe, Roche
• Maria Orr, Principal Pharmacogenetics Advisor to Oncology, AstraZeneca